With 0.63 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.43 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $680.905 whereas the lowest price it dropped to was $661.08. The 52-week range on ARGX shows that it touched its highest point at $689.13 and its lowest point at $475.65 during that stretch. It currently has a 1-year price target of $796.74. Beta for the stock currently stands at 0.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARGX was up-trending over the past week, with a rise of 13.82%, but this was up by 23.61% over a month. Three-month performance surged to 5.30% while six-month performance rose 1.22%. The stock gained 9.56% in the past year, while it has gained 32.32% so far this year. A look at the trailing 12-month EPS for ARGX yields 19.67 with Next year EPS estimates of 23.73. For the next quarter, that number is 4.59. This implies an EPS growth rate of 17.39% for this year and 58.17% for next year.
Float and Shares Shorts:
At present, 61.20 million ARGX shares are outstanding with a float of 60.99 million shares on hand for trading. On 2025-07-15, short shares totaled 1.8 million, which was 293.0 higher than short shares on 1749772800. In addition to Mr. Timothy Van Hauwermeiren EMBA, M.Sc. as the firm’s Co-Founder, CEO & Executive Director, Mr. Karl Gubitz serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.55442 of ARGX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, ARGX reported revenue of $947961000.0 and operating income of $203841000.0. The EBITDA in the recently reported quarter was $239460000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARGX since 15 analysts follow the stock currently. There are 12 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ARGX analysts setting a high price target of 1082.632 and a low target of 561.3611, the average target price over the next 12 months is 798.1185. Based on these targets, ARGX could surge 60.68% to reach the target high and fall by -16.69% to reach the target low. Reaching the average price target will result in a growth of 18.45% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.31562 being high and $1.17905 being low. For ARGX, this leads to a yearly average estimate of $1.66236.
